GWAS in a Small Group of Metabolically Healthy Obese White Adults
Primary Purpose
Obesity
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
GWAS
Sponsored by

About this trial
This is an interventional diagnostic trial for Obesity
Eligibility Criteria
Inclusion Criteria:
- - Adults 40 year old or older
- Caucasian males or females
- BMI ≥ 35 kg/m² or history of BMI ≥ 35 kg/m², or BMi less than 25 kg/m2
- No current or past use of glucose lowering drugs
- No current or past medical history of diabetes mellitus
- No current or past medical history of established coronary artery disease (angina, myocardial infraction, abnormal cardiac stress test)
- No current or past medical history of or treatment for thyroid disorders
- No current or past use of lipid lowering drugs or diagnosis of a lipid disorder
- No current or past medical history of or treatment for hypertension
Subject's willingness to provide the study investigators with a copy of their medical records or give permission to the study investigators to access the following specific medical information:
- Fasting plasma glucose (less than 100 mg/dL/5.6 mmol/L)
- HDL-C cholesterol (more than 40 mg/dL /1.03 mmol/L)
- Total cholesterol (less than 239 mg/dL/ 6.18mmol/L)
- LDL cholesterol (less than 159 mg/dL/4.11 mmol/L)
Exclusion Criteria:
- - Known monogenic forms of obesity
- Polycystic ovary disease (in women)
- Malabsorptive or maldigestive syndromes (Celiac disease, Crohn's Disease, inflammatory bowel disease, etc.)
- Anorexia nervosa or bulimia
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
obese subjects
lean subjects
Arm Description
DNA analysis
DNA analysis
Outcomes
Primary Outcome Measures
number of SNPs associated with high BMI
Using GWAS to identify candidate genes associate with obesity (high BMI) in a carefully phenotyped white adults with obesity (as defined by BMI), metabolically healthy, matched with lean, white adults metabolically healthy.
Secondary Outcome Measures
Full Information
NCT ID
NCT02105909
First Posted
March 26, 2014
Last Updated
April 2, 2014
Sponsor
University of Nevada, Las Vegas
1. Study Identification
Unique Protocol Identification Number
NCT02105909
Brief Title
GWAS in a Small Group of Metabolically Healthy Obese White Adults
Official Title
Genome Wide Association Studies (GWAS) to Identify Candidate Obesity Susceptibility Genes in a Carefully Phenotyped, Metabolically Healthy Population of Obese White Adults
Study Type
Interventional
2. Study Status
Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
May 2009 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
November 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Nevada, Las Vegas
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a GWAS pilot study that aims to identified possible candidate genes associate to obesity by exploring single nucleotide polymorphism (SNP) in a small group of obese , metabolically healthy white adults, matched with lean, white adults , metabolically healthy. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with obesity (as defined by BMI).
Detailed Description
Between 60%-70% of the risk of obesity appears to be heritable. Unfortunately, the exact genes involved have been difficult to identify. New technologies now exist to help researchers discover obesity susceptibility genes. One of these technologies is the Affymetrix Genome-Wide Human SNP (single nucleotide polymorphism) Array 6.0 chips. SNPs are individual base pair differences in genes of different individuals, and they are the main source of human genetic diversity. The "chips" are thumbnail-size silicon surfaces that contain copies of hundreds of thousands of SNPs of the human genome (in this case around 900,000). SNP chips allow researchers to screen thousands of genes in a single experiment and compare genes of subjects with a particular disease or condition with unaffected control subjects. The investigators study utilizes SNP chips to compare the genetic profiles of obese subjects (N = 20, body mass index > 35 kg/m2) without common obesity-related co-morbidities such as diabetes mellitus or hypertension with well matched, lean controls (N = 20, body mass index 18-25 kg/m2). This is a pilot study intended to explore the following: 1) possible associations between obesity and previously unidentified obesity susceptibility genes; 2) associations between known obesity genes and obesity risk in subjects without obesity-related metabolic co-morbidities; and 3) how well our genetic data conform to other studies in similar populations as a way of assessing if the investigators have identified a representative cohort of obese subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
81 (Actual)
8. Arms, Groups, and Interventions
Arm Title
obese subjects
Arm Type
Experimental
Arm Description
DNA analysis
Arm Title
lean subjects
Arm Type
Placebo Comparator
Arm Description
DNA analysis
Intervention Type
Other
Intervention Name(s)
GWAS
Primary Outcome Measure Information:
Title
number of SNPs associated with high BMI
Description
Using GWAS to identify candidate genes associate with obesity (high BMI) in a carefully phenotyped white adults with obesity (as defined by BMI), metabolically healthy, matched with lean, white adults metabolically healthy.
Time Frame
baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
- Adults 40 year old or older
Caucasian males or females
BMI ≥ 35 kg/m² or history of BMI ≥ 35 kg/m², or BMi less than 25 kg/m2
No current or past use of glucose lowering drugs
No current or past medical history of diabetes mellitus
No current or past medical history of established coronary artery disease (angina, myocardial infraction, abnormal cardiac stress test)
No current or past medical history of or treatment for thyroid disorders
No current or past use of lipid lowering drugs or diagnosis of a lipid disorder
No current or past medical history of or treatment for hypertension
Subject's willingness to provide the study investigators with a copy of their medical records or give permission to the study investigators to access the following specific medical information:
Fasting plasma glucose (less than 100 mg/dL/5.6 mmol/L)
HDL-C cholesterol (more than 40 mg/dL /1.03 mmol/L)
Total cholesterol (less than 239 mg/dL/ 6.18mmol/L)
LDL cholesterol (less than 159 mg/dL/4.11 mmol/L)
Exclusion Criteria:
- Known monogenic forms of obesity
Polycystic ovary disease (in women)
Malabsorptive or maldigestive syndromes (Celiac disease, Crohn's Disease, inflammatory bowel disease, etc.)
Anorexia nervosa or bulimia
12. IPD Sharing Statement
Learn more about this trial
GWAS in a Small Group of Metabolically Healthy Obese White Adults
We'll reach out to this number within 24 hrs